» Articles » PMID: 38823406

Inflammatory Risk and Cardiovascular Events in Patients Without Obstructive Coronary Artery Disease: the ORFAN Multicentre, Longitudinal Cohort Study

Abstract

Background: Coronary computed tomography angiography (CCTA) is the first line investigation for chest pain, and it is used to guide revascularisation. However, the widespread adoption of CCTA has revealed a large group of individuals without obstructive coronary artery disease (CAD), with unclear prognosis and management. Measurement of coronary inflammation from CCTA using the perivascular fat attenuation index (FAI) Score could enable cardiovascular risk prediction and guide the management of individuals without obstructive CAD. The Oxford Risk Factors And Non-invasive imaging (ORFAN) study aimed to evaluate the risk profile and event rates among patients undergoing CCTA as part of routine clinical care in the UK National Health Service (NHS); to test the hypothesis that coronary arterial inflammation drives cardiac mortality or major adverse cardiac events (MACE) in patients with or without CAD; and to externally validate the performance of the previously trained artificial intelligence (AI)-Risk prognostic algorithm and the related AI-Risk classification system in a UK population.

Methods: This multicentre, longitudinal cohort study included 40 091 consecutive patients undergoing clinically indicated CCTA in eight UK hospitals, who were followed up for MACE (ie, myocardial infarction, new onset heart failure, or cardiac death) for a median of 2·7 years (IQR 1·4-5·3). The prognostic value of FAI Score in the presence and absence of obstructive CAD was evaluated in 3393 consecutive patients from the two hospitals with the longest follow-up (7·7 years [6·4-9·1]). An AI-enhanced cardiac risk prediction algorithm, which integrates FAI Score, coronary plaque metrics, and clinical risk factors, was then evaluated in this population.

Findings: In the 2·7 year median follow-up period, patients without obstructive CAD (32 533 [81·1%] of 40 091) accounted for 2857 (66·3%) of the 4307 total MACE and 1118 (63·7%) of the 1754 total cardiac deaths in the whole of Cohort A. Increased FAI Score in all the three coronary arteries had an additive impact on the risk for cardiac mortality (hazard ratio [HR] 29·8 [95% CI 13·9-63·9], p<0·001) or MACE (12·6 [8·5-18·6], p<0·001) comparing three vessels with an FAI Score in the top versus bottom quartile for each artery. FAI Score in any coronary artery predicted cardiac mortality and MACE independently from cardiovascular risk factors and the presence or extent of CAD. The AI-Risk classification was positively associated with cardiac mortality (6·75 [5·17-8·82], p<0·001, for very high risk vs low or medium risk) and MACE (4·68 [3·93-5·57], p<0·001 for very high risk vs low or medium risk). Finally, the AI-Risk model was well calibrated against true events.

Interpretation: The FAI Score captures inflammatory risk beyond the current clinical risk stratification and CCTA interpretation, particularly among patients without obstructive CAD. The AI-Risk integrates this information in a prognostic algorithm, which could be used as an alternative to traditional risk factor-based risk calculators.

Funding: British Heart Foundation, NHS-AI award, Innovate UK, National Institute for Health and Care Research, and the Oxford Biomedical Research Centre.

Citing Articles

Coronary Inflammation and Cardiovascular Events in Patients Without Obstructive Coronary Artery Disease.

Diau J, Lange R Curr Cardiol Rep. 2025; 27(1):68.

PMID: 40053166 PMC: 11889004. DOI: 10.1007/s11886-025-02221-y.


Relation of Perivascular Adipose Tissues on Computed Tomography to Coronary Vasospasm.

Asada K, Saito Y, Takaoka H, Kitahara H, Kobayashi Y Rev Cardiovasc Med. 2025; 26(2):26327.

PMID: 40026501 PMC: 11868876. DOI: 10.31083/RCM26327.


Correlation between hemodynamics assessed by FAI combined with CT-FFR and plaque characteristics in coronary artery stenosis.

Duan B, Deng S, Xu R, Wang Y, He K BMC Med Imaging. 2025; 25(1):49.

PMID: 39955520 PMC: 11830200. DOI: 10.1186/s12880-025-01590-8.


Cardiac CT Perfusion Imaging of Pericoronary Adipose Tissue (PCAT) Highlighting Potential Confounds in CTA Analysis.

Wu H, Song Y, Hoori A, Lee J, Al-Kindi S, Huang W J Clin Med. 2025; 14(3).

PMID: 39941441 PMC: 11818118. DOI: 10.3390/jcm14030769.


Evaluating Pericoronary Adipose Tissue Attenuation to Predict Cardiovascular Events: A Multicenter Study in East Asians.

Nishihara T, Miyoshi T, Ejiri K, Osawa K, Fuke S, Seiyama K JACC Asia. 2025; 5(1):1-11.

PMID: 39886202 PMC: 11775815. DOI: 10.1016/j.jacasi.2024.09.009.


References
1.
Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

2.
Cury R, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M . CAD-RADS™ 2.0 - 2022 Coronary Artery Disease-Reporting and Data System: An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR), and.... J Cardiovasc Comput Tomogr. 2022; 16(6):536-557. DOI: 10.1016/j.jcct.2022.07.002. View

3.
. Corrigendum to: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12.... Eur Heart J. 2022; 43(42):4468. DOI: 10.1093/eurheartj/ehac458. View

4.
Gaibazzi N, Martini C, Botti A, Pinazzi A, Bottazzi B, Palumbo A . Coronary Inflammation by Computed Tomography Pericoronary Fat Attenuation in MINOCA and Tako-Tsubo Syndrome. J Am Heart Assoc. 2019; 8(17):e013235. PMC: 6755824. DOI: 10.1161/JAHA.119.013235. View

5.
Puchner S, Liu T, Mayrhofer T, Truong Q, Lee H, Fleg J . High-risk plaque detected on coronary CT angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the ROMICAT-II trial. J Am Coll Cardiol. 2014; 64(7):684-92. PMC: 4135448. DOI: 10.1016/j.jacc.2014.05.039. View